China Botanic Achieves Three Million RMB Sales of New Product
HARBIN, China, Dec. 14, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that as of fiscal year ending October 31, 2010, the Company's new all-natural anti-depressant and nerve regulation product - Compound Schisandra Tablets ("Schisandra Tablets"), a single plant based medicine, has achieved sales of RMB 3.0 million (or $0.5 million) since its launch in July 2010. The sales are in line with management's original estimates.
Schisandra, also known as magnolia vine, has been clinically proven to provide significant benefits to the functioning and regulation of the central nervous system and respiratory systems. According to the traditional Chinese pharmacopoeia, Schisandra is used as a remedy for many ailments, such as those of the kidneys, insomnia and heart palpitations, and is also widely used as treatment for neurasthenia (a term most commonly used in Traditional Chinese medicine to denote a complex of symptoms characterized by chronic fatigue and weakness, loss of memory, and generalized aches and pains).
"Compound Schisandra Tablets complements our existing anti-depressant and nerve regulation Ginseng based product series, and strengthens China Botanic's goal to be the world's leading company specializing in plant-based medicine," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic.. "We are pleased with the initial strong sales and market acceptance of our Schisandra Tablets, which are in line with our sales forecast. This reflects well on our thorough market research and sales and marketing strategy. We will continue to develop market oriented all-natural plant based products to capitalize on the attractive market opportunities."<